WO2004014336A3 - Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin - Google Patents

Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin Download PDF

Info

Publication number
WO2004014336A3
WO2004014336A3 PCT/EP2003/008828 EP0308828W WO2004014336A3 WO 2004014336 A3 WO2004014336 A3 WO 2004014336A3 EP 0308828 W EP0308828 W EP 0308828W WO 2004014336 A3 WO2004014336 A3 WO 2004014336A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
receptor antagonists
buprenorphine
transdermal systems
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008828
Other languages
English (en)
French (fr)
Other versions
WO2004014336A2 (de
Inventor
Johannes Bartholomaeus
Heinrich Kugelmann
Eric-Paul Paques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002137057 external-priority patent/DE10237057A1/de
Priority claimed from DE2002137056 external-priority patent/DE10237056A1/de
Priority to DE50307717T priority Critical patent/DE50307717D1/de
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to DK03775130T priority patent/DK1526848T3/da
Priority to EP03775130A priority patent/EP1526848B1/de
Priority to SI200330945T priority patent/SI1526848T1/sl
Priority to AU2003283055A priority patent/AU2003283055A1/en
Publication of WO2004014336A2 publication Critical patent/WO2004014336A2/de
Publication of WO2004014336A3 publication Critical patent/WO2004014336A3/de
Priority to US11/052,116 priority patent/US20050191340A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft Opiod-Rezeptor-Antagonisten, wie beispielsweise Naloxon, in transdermalen Applikationsformen mit mindestens Buprenorphin als Wirkstoff.
PCT/EP2003/008828 2002-08-09 2003-08-08 Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin Ceased WO2004014336A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003283055A AU2003283055A1 (en) 2002-08-09 2003-08-08 Opioid-receptor antagonists in transdermal systems having buprenorphine
SI200330945T SI1526848T1 (sl) 2002-08-09 2003-08-08 Opioidni receptorski antagonisti v transdermalnihsistemih z buprenorfinom
DE50307717T DE50307717D1 (de) 2002-08-09 2003-08-08 Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
DK03775130T DK1526848T3 (da) 2002-08-09 2003-08-08 Opiod-receptorantagonister i transdermale systemer med buprenorphin
EP03775130A EP1526848B1 (de) 2002-08-09 2003-08-08 Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
US11/052,116 US20050191340A1 (en) 2002-08-09 2005-02-08 Opioid-receptor antagonists in transdermal systems having buprenorphine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2002137057 DE10237057A1 (de) 2002-08-09 2002-08-09 Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
DE10237056.7 2002-08-09
DE10237057.5 2002-08-09
DE2002137056 DE10237056A1 (de) 2002-08-09 2002-08-09 Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/052,116 Continuation US20050191340A1 (en) 2002-08-09 2005-02-08 Opioid-receptor antagonists in transdermal systems having buprenorphine

Publications (2)

Publication Number Publication Date
WO2004014336A2 WO2004014336A2 (de) 2004-02-19
WO2004014336A3 true WO2004014336A3 (de) 2004-12-09

Family

ID=31716605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008828 Ceased WO2004014336A2 (de) 2002-08-09 2003-08-08 Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin

Country Status (9)

Country Link
EP (1) EP1526848B1 (de)
AT (1) ATE367155T1 (de)
AU (1) AU2003283055A1 (de)
CY (1) CY1107739T1 (de)
DE (1) DE50307717D1 (de)
DK (1) DK1526848T3 (de)
ES (1) ES2290512T3 (de)
PT (1) PT1526848E (de)
WO (1) WO2004014336A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447015A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
AP2015008920A0 (en) 2013-06-04 2015-12-31 Lohmann Therapie Syst Lts Transdermal delivery system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430019A2 (de) * 1989-11-29 1991-06-05 LTS Lohmann Therapie-Systeme GmbH & Co. KG Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil
WO1997033566A2 (en) * 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
EP0819438A2 (de) * 1996-07-19 1998-01-21 Nitto Denko Corporation Buprenorphine enthaltendes Präparat für perkutäne Absorption
WO1998036728A2 (en) * 1997-02-24 1998-08-27 Euro-Celtique, S.A. Sustained analgesia achieved with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430019A2 (de) * 1989-11-29 1991-06-05 LTS Lohmann Therapie-Systeme GmbH & Co. KG Transdermales therapeutisches System mit Buprenorphin als aktivem Bestandteil
WO1997033566A2 (en) * 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
EP0819438A2 (de) * 1996-07-19 1998-01-21 Nitto Denko Corporation Buprenorphine enthaltendes Präparat für perkutäne Absorption
WO1998036728A2 (en) * 1997-02-24 1998-08-27 Euro-Celtique, S.A. Sustained analgesia achieved with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORKOWSKI K.: "k-Opioid agonist induced diuresis.", CAN. J. PHYSIOL. PHARMACOL., vol. 67, 1989, pages 1219 - 1224, XP009029870 *
HAYES A G ET AL: "EVALUATION OF THE RECEPTOR SELECTIVITIES OF OPIOID DRUGS BY INVESTIGATING THE BLOCK OF THEIR EFFECT ON URINE OUTPUT BY BETA-FUNALTREXAMINE", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 240, no. 3, 1987, pages 984 - 988, XP001064229, ISSN: 0022-3565 *
LEANDER J D: "BUPRENORPHINE HAS POTENT KAPPA OPIOID RECEPTOR ANTAGONIST ACTIVITY", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 26, no. 9, 1987, pages 1445 - 1447, XP001064223, ISSN: 0028-3908 *
MARK L. ET. AL.: "Buprenorphine is an Antagonist at the k Opioid Receptor", PHARMACEUTICAL RESEARCH, 1985, pages 178 - 181, XP009029866 *

Also Published As

Publication number Publication date
DE50307717D1 (de) 2007-08-30
EP1526848A2 (de) 2005-05-04
AU2003283055A1 (en) 2004-02-25
DK1526848T3 (da) 2007-10-22
EP1526848B1 (de) 2007-07-18
ES2290512T3 (es) 2008-02-16
PT1526848E (pt) 2007-08-08
WO2004014336A2 (de) 2004-02-19
ATE367155T1 (de) 2007-08-15
AU2003283055A8 (en) 2004-02-25
CY1107739T1 (el) 2013-04-18

Similar Documents

Publication Publication Date Title
WO2003077867A3 (en) Naltrexone hydrochloride compositions
WO2003097608A3 (en) Opioid and opioid-like compounds and uses thereof
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
WO2005041891A3 (en) Neutrophil activation by immune response modifier compounds
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2005053612A3 (en) Micellar systems useful for delivery of lipophilic or hydrophobic compounds
WO2005045689A8 (en) Methods and systems for network coordination
WO2004027822A3 (en) Oriented nanostructures and methods of preparing
AU2002210952A1 (en) Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
TWI328576B (en) Diketohydrazine derivative compound, medicament containing same as active ingredient
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2005007141A3 (en) Ubiquitin ligase inhibitors and methods related thereto
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2003099192A3 (en) Bis-aromatic alkanols
CY1107739T1 (el) Ανταγωνιστες υποδοχεων οπιοειδων σε διαδερματικα συστηματα με μπουπρενορφινη
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EP1416253A3 (de) Aktive Sicherheitsbarriere
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof
WO2006076504A3 (en) Sialic acid permease system
AU2003263978A1 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
AU2001234208A1 (en) Antagonists for nicotinic acetylcholine receptor, which are containing borneol or camphor as an active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003775130

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11052116

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003775130

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2003775130

Country of ref document: EP